ATM

Lilly's Stock Takes a Hit Following Trump's Withdrawal of Medicare Obesity Treatment Proposal

3 days ago

In a surprising turn of events, shares of pharmaceutical giant Eli Lilly experienced a notable decline after former President Donald Trump announced that he would not be proceeding with a proposal to include obesity treatments under Medicare coverage. This unexpected withdrawal has sent ripples through the investor community, raising concerns about the potential impact on Lilly's lucrative weight-loss medications.

Trump Rejects Biden's Medicare Obesity Drug Coverage Proposal, Sparks Controversy

6 days ago

In a significant move that is stirring considerable debate, former President Donald Trump has publicly dismissed President Joe Biden's proposal aimed at expanding Medicare coverage for obesity treatment drugs. This decision aligns with Trump’s ongoing strategy to position himself as a staunch opponent of Biden's healthcare initiatives, which he argues could lead to increased costs and government overreach.

Amgen Secures FDA Approval for Uplizna, Paving the Way for Enhanced Treatment of Rare Disease

7 days ago

In a significant development in the biopharmaceutical sector, Amgen has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug, Uplizna, aimed at treating a rare and often debilitating disease. This approval marks a critical advancement not only for Amgen but also for patients suffering from this condition, which has been challenging to manage with existing therapies.

Potential Tariffs on Botox Products Could Increase Prices for Users in Ireland

8 days ago

Users of Botox, the acclaimed cosmetic treatment known for smoothing out wrinkles, may soon find themselves facing increased costs as Ireland considers implementing new tariffs. These tariffs are being contemplated as part of a broader trade strategy, and experts suggest that this move could directly impact both the price and availability of Botox in the region.

Chinese Biotech Aims for U.S. Approval of Groundbreaking Cancer Therapy as Merck Faces Competition

10 days ago

In a bold move signaling the intense competition within the biotechnology sector, a Chinese biotech company is seeking to secure regulatory approval for its innovative cancer therapy in the United States. This development comes as Merck & Co., a leading global player in cancer treatments, faces potential competition that could disrupt its established market dominance.

Hindustan Aeronautics Secures Historic $7.3 Billion Defense Order

13 days ago

In a significant development for India's defense sector, Hindustan Aeronautics Limited (HAL) has received an unprecedented order worth $7.3 billion from the Indian Ministry of Defence. This monumental order is understood to include the supply of 70 aircraft, which could potentially bolster the nation’s military capabilities in alignment with its strategic objectives.

J&J Surpasses AstraZeneca in High-Stakes Cancer Treatment Race

15 days ago

In a significant turn of events in the highly competitive landscape of cancer therapies, Johnson & Johnson (J&J) has outpaced AstraZeneca in the race to deliver a groundbreaking treatment for patients suffering from advanced forms of cancer. This pivotal moment comes as both pharmaceutical giants have been relentlessly advancing their respective drug candidates, aiming to claim a larger share of the lucrative oncology market.

Massive $2 Billion Collaboration: Novo Nordisk Teams Up with United Labs for Breakthrough Obesity Drug

18 days ago

In a significant development in the pharmaceutical sector, Novo Nordisk has inked a groundbreaking $2 billion deal with United Labs aimed at advancing the research and development of a promising obesity treatment. This strategic partnership is expected to bolster efforts to combat obesity, a growing health crisis affecting millions globally.

Alnylam Secures Expanded Approval for Heart Drug, Paving the Way for Competition with Pfizer

21 days ago

In a significant development within the pharmaceutical industry, Alnylam Pharmaceuticals has received an expanded approval for its heart disease treatment, a move that positions the company squarely in competition with industry giant Pfizer. This latest FDA endorsement is expected to have profound implications for both companies and the market at large, particularly as the demand for innovative cardiovascular therapies continues to rise.

Roche Joins Forces with Zealand Pharma in a $5.3 Billion Deal to Combat Obesity

30 days ago

In a significant move within the pharmaceutical industry, Swiss giant Roche Holding AG has entered into a transformative agreement with Denmark's Zealand Pharma A/S, aimed at tackling the growing global epidemic of obesity. The partnership is valued at an impressive $5.3 billion, positioning both companies at the forefront of innovation in weight management therapeutics.